GUANFACINE HYDROCHLORIDE (guanfacine) by Rubicon Biotechnology is 2a -adrenergic receptor agonist. Approved for attention deficit hyperactivity disorder (adhd), adjunctive therapy to stimulant medications [see clinical studies (14)], adjunctive therapy to stimulant medications (1. First approved in 2023.
Drug data last refreshed 20h ago
2A -adrenergic receptor agonist. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of guanfacine in ADHD is not known.
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Worked on GUANFACINE HYDROCHLORIDE at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.